premier global longevity company

Rubedo discovers and develops medicines to keep you biologically young by targeting the pathologic cells that drive aging

Keeping you
biologically young

Rubedo discovers and develops medicines to keep you biologically young by targeting the pathologic cells that drive aging.

Rubedo / rōō-bē′dō / n. 1. a Latin word meaning “redness” that represents an alchemist’s final stage of great work to create the universal medicine that provides longevity and youth and cures all disease.

Rubedo develops medicines to keep you biologically young

Rubedo Life Sciences was founded by a group of leading scientists and entrepreneurs with a life-long passion for the science of aging and making therapeutics to help people live a better life longer.

They joined forces to merge their knowledge and expertise into a crucible of innovations.

Newsfeed

August 25, 2022

Aging Research & Drug Discovery Meeting 2022

June 13, 2022

Rubedo Life Sciences Announces Expansion of Scientific Advisory Board

April 13, 2022

Rubedo wins the Biotechnology Award 2022

Investors

Improving health span

Cory Hogaboam, PhD

Cedars-Sinai Professor of Medicine, Chronic Lung Diseases

Dr. Cory M. Hogaboam, PhD is a Professor of Medicine in the Women’s Guild Lung Institute at Cedars Sinai Medical Center. Dr. Hogaboam is also an Adjunct Professor of Pathology at the University of Michigan Medical School. His research group currently employs genomic, proteomic and bioinformatic approaches to analyze mechanisms contributing to fibrotic and immune system-directed responses in idiopathic pulmonary fibrosis (IPF), lung cancer, sarcoid, hypersensitivity pneumonitis, chronic obstructive pulmonary disease (COPD), and asthma utilizing human tissue- and blood-derived cells including fibroblasts, mesenchymal progenitors and various immune cell types that are typically present in abundance in these pulmonary diseases. His group also uses translational approaches through the development of humanized SCID mouse models of IPF, cancer, and asthma. He earned a Bachelor of Science degree in Zoology from the University of Calgary, AB, Canada in 1989. He also holds a Doctorate in Pharmacology (1993) from the same institution. Dr. Hogaboam then engaged in Postdoctoral training in Immunology at McMaster University, Hamilton, ON, Canada from 1993 to 1996. In 1996, Dr. Hogaboam joined the faculty of the Department of Pathology at the University of Michigan Medical School as a Visiting Scholar. He became a faculty member of the Department at the rank of Research Investigator in 1998, Assistant Professor in 2002, Associate Professor in 2004, and full Professor in 2008. Dr. Hogaboam joined the faculty at Cedars Sinai Medical Center in September of 2013. Hogaboam is a member of several professional organizations including the American Association of Immunologists, the American Thoracic Society, and the American Association of Allergy, Asthma and Immunology. He is presently serving on the editorial board of the American Journal of Respiratory and Critical Care Medicine and the Journal of Clinical Investigation Insight. Dr. Hogaboam has authored or co-authored approximately 281 peer-reviewed manuscripts and 31 book chapters. He has authored or co-authored 11 patents on therapeutic interventions for lung and liver. Dr. Hogaboam has received financial research support from the National Institutes of Health, American Lung Association, Canadian Institutes of Health Research, and several Industry sponsors.